A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
| Author | |
|---|---|
| Abstract | :
Sorafenib has been demonstrated as second-line therapy, with limited significant adverse events at a dose of 400 mg twice a day (b.i.d.) in patients with metastatic renal cell carcinoma. This study evaluated the ability of patients to dose-escalate, response rate, progression-free survival (PFS), and overall survival. |
| Year of Publication | :
2012
|
| Journal | :
Clinical genitourinary cancer
|
| Volume | :
10
|
| Issue | :
3
|
| Number of Pages | :
153-8
|
| ISSN Number | :
1558-7673
|
| URL | :
https://linkinghub.elsevier.com/retrieve/pii/S1558-7673(12)00052-3
|
| DOI | :
10.1016/j.clgc.2012.03.001
|
| Short Title | :
Clin Genitourin Cancer
|
| Download citation |